A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

Sponsor
Almirall, S.A.
Study ID
NCT07547813
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LAD328 — DRUG
    LAD328 administered intravenously.
  • Placebo — OTHER
    Placebo administered intravenously.

Study Details

The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.

Key Dates

First listed
Apr 23, 2026
Start date
May 13, 2026
Status verified
Jun 2026
Primary completion
Feb 28, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LAD328
    Participants will receive LAD328 Dose A, intravenous (IV) infusion.
  • Placebo Comparator: Placebo
    Participants will receive placebo diluent solution for IV infusion.

Primary Outcome Measure

Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55) [ Time Frame: At Week 12 ]

Central Contacts

Find similar trials

Nationwide
Hidradenitis suppurativa trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies